Urgent.News

What's breaking now, across thousands of outlets.

Business

Delayed salaries, leadership change: Inside Helium Health’s difficult year

On November 4, employees at Helium Health received an email thanking them for staying with the company through “challenging moments.”

Delayed salaries, leadership change: Inside Helium Health’s difficult year

Helium Health, a Lagos-based healthtech startup, faced a difficult year marked by a leadership change and delayed salaries. On November 4, the company's People & Culture team sent an internal email to employees, thanking them for their commitment during "challenging moments" and confirming that outstanding allowances had been settled.

The same day, Helium Health announced a ₦3.4 billion grant from Google.org, which will be used to develop artificial intelligence tools to flag pregnancy risks and improve maternal care in four Nigerian states. CEO Dimeji Sofowora stated that the timing of these events was coincidental, but together they signified a return to normalcy for the startup.

The salary delays were attributed to "temporary cash-flow timing," and the company kept staff informed throughout the process. Despite these challenges, Helium Health has not announced an equity round since its $30 million Series B in 2023, which was largely used to fuel its lending arm for hospitals, clinics, and pharmacies. The healthtech sector in Nigeria has seen a contraction, with 40 startups becoming inactive between 2020 and 2025 due to infrastructure challenges, difficulty making money servicing hospitals, and a funding slowdown.

Written by urgent.news from TechCabal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at techcabal.com →

More in Business

Celltrion Extends Biosimilar Lead Across Asia

Celltrion is solidifying its dominance in the Asian region, a representative pharmerging (emerging pharmaceutical) market, driven by the overwhelming market share of its flagship product lineup for…

  • Celltrion maintains 95% market share in Singapore for autoimmune treatment Remsima.
  • Herzuma ranks first in Hong Kong, Thailand, and Malaysia for breast and gastric cancer.
  • Truxima secures 92% market share in Singapore for blood cancer treatment.

More from Thursday 19 November →